0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
Liraglutide and Semaglutide - Global Strategic Business Report - Product Thumbnail Image

Liraglutide and Semaglutide - Global Strategic Business Report

  • Report
  • November 2025
  • 451 Pages
  • Global
From
EUR$5,850USDGBP
Diabetic Ulcers Treatment - Global Strategic Business Report - Product Thumbnail Image

Diabetic Ulcers Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 384 Pages
  • Global
From
EUR$5,850USDGBP
Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Thumbnail Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 273 Pages
  • Global
From
EUR$5,850USDGBP
DPP-IV Inhibitors - Global Strategic Business Report - Product Thumbnail Image

DPP-IV Inhibitors - Global Strategic Business Report

  • Report
  • November 2025
  • 262 Pages
  • Global
From
EUR$5,850USDGBP
Fabry Disease Treatment - Global Strategic Business Report - Product Thumbnail Image

Fabry Disease Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 367 Pages
  • Global
From
EUR$5,850USDGBP
Insulin Injection Aids - Global Strategic Business Report - Product Thumbnail Image

Insulin Injection Aids - Global Strategic Business Report

  • Report
  • November 2025
  • 280 Pages
  • Global
From
EUR$5,850USDGBP
Trulicity - Global Strategic Business Report - Product Thumbnail Image

Trulicity - Global Strategic Business Report

  • Report
  • November 2025
  • 471 Pages
  • Global
From
EUR$5,850USDGBP
Oral Anti-Diabetic Drugs - Global Strategic Business Report - Product Thumbnail Image

Oral Anti-Diabetic Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 197 Pages
  • Global
From
EUR$5,850USDGBP
Basal Insulin - Global Strategic Business Report - Product Thumbnail Image

Basal Insulin - Global Strategic Business Report

  • Report
  • November 2025
  • 179 Pages
  • Global
From
EUR$5,850USDGBP
Human Recombinant Insulin - Global Strategic Business Report - Product Thumbnail Image

Human Recombinant Insulin - Global Strategic Business Report

  • Report
  • November 2025
  • 189 Pages
  • Global
From
EUR$5,850USDGBP
From
EUR$5,850USDGBP
From
EUR$5,850USDGBP
Sulfonylureas - Global Strategic Business Report - Product Thumbnail Image

Sulfonylureas - Global Strategic Business Report

  • Report
  • November 2025
  • 362 Pages
  • Global
From
EUR$5,850USDGBP
From
EUR$5,850USDGBP
From
EUR$5,850USDGBP
Diabetes Drugs - Global Strategic Business Report - Product Thumbnail Image

Diabetes Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 196 Pages
  • Global
From
EUR$5,850USDGBP
Gaucher Disease Treatment - Global Strategic Business Report - Product Thumbnail Image

Gaucher Disease Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 194 Pages
  • Global
From
EUR$5,850USDGBP
Diabetic Nephropathy Treatment - Global Strategic Business Report - Product Thumbnail Image

Diabetic Nephropathy Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 196 Pages
  • Global
From
EUR$5,850USDGBP
Krabbe Disease Treatment - Global Strategic Business Report - Product Thumbnail Image

Krabbe Disease Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 194 Pages
  • Global
From
EUR$5,850USDGBP
Male Hypogonadism - Global Strategic Business Report - Product Thumbnail Image

Male Hypogonadism - Global Strategic Business Report

  • Report
  • November 2025
  • 197 Pages
  • Global
From
EUR$5,850USDGBP
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more